Veru Inc (OQ:VERU)
Business Focus: Birth Control Products
| Sector: Consumer Non-Cyclicals | Industry: Personal Products |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 2916 N. MIAMI AVENUE, SUITE 1000 MIAMI FL 33127 |
| Tel: | 1-800-9720538 |
| Website: | https://verupharma.com |
| IR: | See website |
| Key People | ||
| Mitchell S. Steiner Chairman of the Board, President, Chief Executive Officer | Harry Fisch Vice Chairman of the Board, Chief Corporate Officer | Michele Greco Chief Financial Officer, Chief Administrative Officer | K. Gary Barnette Chief Scientific Officer |
| Business Overview |
| Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate. |
| Financial Overview |
| For the three months ended 31 December 2023, Veru Inc revenues decreased 15% to $2.1M. Net loss decreased 79% to $8.3M. Revenues reflect ENTADFI segment decrease from $8K to $0K, Other Countries segment decrease of 46% to $785K, Uganda segment decrease from $257K to $0K. Lower net loss reflects Research and Development - Balancing va decrease of 94% to $1.2M (expense), Selling, general and administrative - Ba decrease of 61% to $5.5M (expense). |
| Employees: | 189 as of Oct 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $146.25M as of Dec 31, 2023 |
| Annual revenue (TTM): | $15.93M as of Dec 31, 2023 |
| EBITDA (TTM): | -$68.54M as of Dec 31, 2023 |
| Net annual income (TTM): | -$64.59M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$59.88M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 146,381,186 as of Mar 29, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.